Search Results
Showing 46 results
Filters
Disease State
Alliance
Content Type
Location
FAQ: What Is the Total Improvement Score and How Should It Be Interpreted in IIM Clinical Trials?
In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, explains the Total Improvement Score, or TIS, and how it is ...
September 10, 2026
FAQ: What Is the Role of Autoantibodies in Disease Progression and Treatment Response in IIM?
In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, discusses how autoantibodies help guide diagnosis, prognosis...
September 02, 2026
New Treatment Options for MASH
In this educational overview, Summer Collier, DNP, RN, FNP-BC at UC San Diego Health, discusses semaglutide as an FDA-approved treatment option for adults with noncirrhotic metabolic dysfunction-as...
August 31, 2026
FAQ: What Are Key Diagnostic Considerations and Limitations of Antibody Testing in IIM?
In this FAQ video module, Jennifer Mylod, nurse practitioner with Arizona Arthritis Rheumatology Associates in Phoenix, Arizona, discusses key diagnostic considerations and limitations of antibody ...
August 27, 2026
Importance of Early Recognition in ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
Connective Tissue Diseases and ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
Consolidation Patterns in ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
FAQ: How Can Pulmonology and Rheumatology Providers Coordinate Earlier PH-ILD Diagnosis?
In this ILD Community Network video, Kelsey Cramer, NP, an interstitial lung disease and pulmonary hypertension specialist from the Medical College of Wisconsin and Froedtert Hospital, discusses ho...
August 04, 2026
FAQ: How Do Clinical Manifestations and Histopathologic Features Vary Across Myositis Subtypes?
In this rheumatology FAQ, Audrey Gibson, PA-C, reviews how clinical manifestations and histopathologic features vary across idiopathic inflammatory myopathy subtypes, including dermatomyositis, pol...
July 28, 2026
How To Differentiate ILD Progression vs Treatment Failure
In this episode of the ILD Community Network Podcast, host Amanda Mixon, PA-C, is joined by Jenny Williams, PA-C, for a practical discussion on how clinicians can differentiate interstitial lung di...
July 22, 2026
FAQ: What Are the Key Unmet Needs in the Treatment of Idiopathic Inflammatory Myopathies?
In this rheumatology FAQ, host Audrey Gibson, PA-C from the Arthritis Center of North Georgia in Gainesville, Georgia, discusses the key unmet needs in the treatment of idiopathic inflammatory myop...
July 21, 2026
FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
In this educational FAQ video, Iris Zink, NP, a rheumatology nurse practitioner, provides a comprehensive overview of the TYK2/STAT signaling pathway and its immunologic role in autoimmune diseases...
May 28, 2026
FAQ: What Is the Total Improvement Score and How Should It Be Interpreted in IIM Clinical Trials?
In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, explains the Total Improvement Score, or TIS, and how it is ...
September 10, 2026
FAQ: What Is the Role of Autoantibodies in Disease Progression and Treatment Response in IIM?
In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, discusses how autoantibodies help guide diagnosis, prognosis...
September 02, 2026
New Treatment Options for MASH
In this educational overview, Summer Collier, DNP, RN, FNP-BC at UC San Diego Health, discusses semaglutide as an FDA-approved treatment option for adults with noncirrhotic metabolic dysfunction-as...
August 31, 2026
FAQ: What Are Key Diagnostic Considerations and Limitations of Antibody Testing in IIM?
In this FAQ video module, Jennifer Mylod, nurse practitioner with Arizona Arthritis Rheumatology Associates in Phoenix, Arizona, discusses key diagnostic considerations and limitations of antibody ...
August 27, 2026
Importance of Early Recognition in ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
Connective Tissue Diseases and ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
Consolidation Patterns in ILD
Check out content from the 2026 APAPP National Conference.
August 14, 2026
FAQ: How Can Pulmonology and Rheumatology Providers Coordinate Earlier PH-ILD Diagnosis?
In this ILD Community Network video, Kelsey Cramer, NP, an interstitial lung disease and pulmonary hypertension specialist from the Medical College of Wisconsin and Froedtert Hospital, discusses ho...
August 04, 2026
FAQ: How Do Clinical Manifestations and Histopathologic Features Vary Across Myositis Subtypes?
In this rheumatology FAQ, Audrey Gibson, PA-C, reviews how clinical manifestations and histopathologic features vary across idiopathic inflammatory myopathy subtypes, including dermatomyositis, pol...
July 28, 2026
How To Differentiate ILD Progression vs Treatment Failure
In this episode of the ILD Community Network Podcast, host Amanda Mixon, PA-C, is joined by Jenny Williams, PA-C, for a practical discussion on how clinicians can differentiate interstitial lung di...
July 22, 2026
FAQ: What Are the Key Unmet Needs in the Treatment of Idiopathic Inflammatory Myopathies?
In this rheumatology FAQ, host Audrey Gibson, PA-C from the Arthritis Center of North Georgia in Gainesville, Georgia, discusses the key unmet needs in the treatment of idiopathic inflammatory myop...
July 21, 2026
FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
In this educational FAQ video, Iris Zink, NP, a rheumatology nurse practitioner, provides a comprehensive overview of the TYK2/STAT signaling pathway and its immunologic role in autoimmune diseases...
May 28, 2026
One hub. Every specialty. Unified.
Connect with fellow APPs and access exclusive educational resources.
Explore Alliances